Literature DB >> 18929442

Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer.

Youqing Liu1, Hui Xing, Danhui Weng, Xiaohong Song, Xiaomin Qin, Xi Xia, Yanjie Weng, Fengqi Liang, Gang Chen, Xiaobing Han, Xiaoli Ma, Shixuan Wang, Jianfeng Zhou, Gang Xu, Li Meng, Ding Ma.   

Abstract

Cervical cancer still remains a major health problem in women worldwide. Inhibitors of topoisomerase I have proven to be among the most promising new classes of anti-neoplastic agents introducing into the clinic in recent years. CPT-11 is one of the most widely used Camptothecin analogues and is converted to form the active metabolite SN-38. The study tried to explore the in vitro mechanisms of apoptosis induced by SN-38 in cervical cancer cell lines HeLa and SiHa. The results demonstrated here that SN-38 inhibited cell proliferation in a time- and dose-dependant manner. Western Blot showed that SN-38 down-regulated protein expression of p-Akt and increased protein expression of p53 and p21, but it had no effects on protein expression of Bax, Bcl-2 and Akt. Transfection of the full-length Akt cDNA into HeLa and SiHa cells resulted in the reduction of apoptosis induced by SN-38, and Akt kinase activity regulated the p53 pathway, indicating that inhibition of the Akt pathway played an important role in exhibition of SN-38-mediated cytotoxic effect. Our data suggested that SN-38 could induce apoptosis through a p53 pathway and that activation of p53 in response to S-38 is governed by Akt.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18929442     DOI: 10.1016/j.canlet.2008.08.037

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.

Authors:  Emanuele Perrone; Paola Manara; Salvatore Lopez; Stefania Bellone; Elena Bonazzoli; Aranzazu Manzano; Luca Zammataro; Anna Bianchi; Burak Zeybek; Natalia Buza; Joan Tymon-Rosario; Gary Altwerger; Chanhee Han; Gulden Menderes; Gloria S Huang; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Pei Hui; Peter E Schwartz; Giovanni Scambia; Alessandro D Santin
Journal:  Mol Oncol       Date:  2020-01-14       Impact factor: 6.603

2.  3EZ,20Ac-ingenol, a catalytic inhibitor of topoisomerases, downregulates p-Akt and induces DSBs and apoptosis of DT40 cells.

Authors:  Yasuaki Fukuda; Masahiro Kanbe; Manami Watanabe; Katsuaki Dan; Keiichi Matsuzaki; Susumu Kitanaka; Shohei Miyata
Journal:  Arch Pharm Res       Date:  2013-04-18       Impact factor: 4.946

3.  Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.

Authors:  Salvatore Lopez; Emanuele Perrone; Stefania Bellone; Elena Bonazzoli; Burak Zeybek; Chanhee Han; Joan Tymon-Rosario; Gary Altwerger; Gulden Menderes; Anna Bianchi; Luca Zammataro; Aranzazu Manzano; Paola Manara; Elena Ratner; Dan-Arin Silasi; Gloria S Huang; Masoud Azodi; Peter E Schwartz; Francesco Raspagliesi; Roberto Angioli; Natalia Buza; Pei Hui; Heather M Bond; Alessandro D Santin
Journal:  Oncotarget       Date:  2020-02-04

4.  T-box transcription factor TBX1, targeted by microRNA-6727-5p, inhibits cell growth and enhances cisplatin chemosensitivity of cervical cancer cells through AKT and MAPK pathways.

Authors:  Haixia Liu; Mei Song; Xiaoyan Sun; Xin Zhang; Huayan Miao; Yankui Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.